Poster presentation demonstrates the differentiated profile and broad applicability of the company’s gene silencing platform

Mon, 15/05/2023 - 00:00

London, UK, 15th May 2023 / Sciad Newswire / Laverock Therapeutics Ltd today announces that a key update on its proprietary and differentiated gene editing induced gene silencing (GEiGS) platform will be featured at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) taking place May 16-20, 2023, in Los Angeles.

The data that will be presented at ASGCT demonstrates important stability, tunability and programmability attributes of the gene silencing approach in the context of iPSCs, primary T-cells and iPSC-derived myeloid cells. The presentation will provide fundamental insight into the power of the GEiGS platform for advanced cell therapy development, and its differentiation from classical gene editing and shRNA/siRNA approaches.

“This data opens up our ability to create a therapeutic pipeline of next-generation cell therapies in both regenerative medicine and immuno-oncology areas. We believe this technology can help solve many of the challenges remaining in the cell therapy field, ultimately improving efficacy, safety and accessibility,” said David Venables, CEO at Laverock Therapeutics.

“Laverock is continuing to develop its internal assets, while seeking partnerships and co-development options to expedite key activities. We look forward to providing further updates in the coming months.”

Details of the presentation are as follows:

  • Title: Engineering Therapeutic Cells Through Rewiring of the miRNA Network
  • Date/time of poster presentation session: Wednesday, May 17 at 12pm. Poster will be on display for the duration of the event.
  • Lead author: Anna Klucnika
  • Presenting author: Vlad C. Seitan
  • Poster number: 759
  • View the abstract

ENDS

Notes to editors

About Laverock Therapeutics
Laverock Therapeutics was established in 2021 to develop and commercialise the gene editing induced gene silencing (GEiGS) platform for human therapeutic applications. We believe this technology provides significant advantages over current approaches and enables the development of next-generation, programmable ex-vivo cell therapies.

Laverock has its headquarters in London, UK. For more information, please visit www.laverocktx.com and follow us on LinkedIn.

For further information, please contact:

Laverock Therapeutics
E: contact@laverocktx.com

Sciad Communications
E: pressteam@sciad.com
T: +44 (0)20 3405 7892

Biotechnology
Life Science
Press Release